Stockholm - Delayed Quote SEK

Genovis AB (publ.) (GENO.ST)

Compare
24.90
-0.10
(-0.40%)
At close: 5:29:30 PM GMT+1
Loading Chart for GENO.ST
DELL
  • Previous Close 25.00
  • Open 25.00
  • Bid 24.55 x --
  • Ask 24.85 x --
  • Day's Range 24.40 - 25.25
  • 52 Week Range 19.00 - 53.00
  • Volume 51,719
  • Avg. Volume 79,103
  • Market Cap (intraday) 1.63B
  • Beta (5Y Monthly) 1.64
  • PE Ratio (TTM) 59.29
  • EPS (TTM) 0.42
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 39.00

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. In addition, the company offers GingisREX, a protease that digests proteins C-terminally of arginine residues; GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; and OpeRATOR, an O-glycan-specific protease. Further, it provides OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; GlycOCATCH, an affinity resin; GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a goat polyclonal antibody; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody. Additionally, the company offers antibodies, assay kits, reagents, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services, as well as operates an online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Europe, North America, and Asia. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

www.genovis.com

37

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GENO.ST

View More

Performance Overview: GENO.ST

Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

GENO.ST
0.81%
OMX Stockholm 30 Index
5.41%

1-Year Return

GENO.ST
50.60%
OMX Stockholm 30 Index
12.64%

3-Year Return

GENO.ST
56.77%
OMX Stockholm 30 Index
10.99%

5-Year Return

GENO.ST
2.35%
OMX Stockholm 30 Index
44.42%

Compare To: GENO.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GENO.ST

View More

Valuation Measures

As of 1/16/2025
  • Market Cap

    1.64B

  • Enterprise Value

    1.59B

  • Trailing P/E

    59.52

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.62

  • Price/Book (mrq)

    7.37

  • Enterprise Value/Revenue

    12.28

  • Enterprise Value/EBITDA

    29.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.49%

  • Return on Assets (ttm)

    6.03%

  • Return on Equity (ttm)

    8.75%

  • Revenue (ttm)

    127.86M

  • Net Income Avi to Common (ttm)

    17.25M

  • Diluted EPS (ttm)

    0.42

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    135.81M

  • Total Debt/Equity (mrq)

    37.33%

  • Levered Free Cash Flow (ttm)

    13.69M

Research Analysis: GENO.ST

View More

People Also Watch